Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
AbstractA recently published article described the safety, tolerability, and pharmacokinetic profile of molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). Here, we report an unprecedented collaboration between sponsor, contract research organization (CRO), and regulatory authorities that enabled accelerated generation of these phase I data, including administration of the first-in-human (FIH) dose of molnupiravir within 5 days of receiving regulatory approval in ...
Source: Trials - August 23, 2021 Category: Research Source Type: clinical trials
Prevalence And Burden Of Nausea And Vomiting In Pregnant Women
Conditions: Nausea Gravidarum; Vomiting of Pregnancy Intervention: Other: Survey Sponsors: Italfarmaco; Opera Contract Research Organization a Tigermed company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2021 Category: Research Source Type: clinical trials
